BPG is committed to discovery and dissemination of knowledge
Prospective Study
Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Nephrol. Sep 25, 2026; 15(3): 119581
Published online Sep 25, 2026. doi: 10.5527/wjn.119581
Integrated biomarkers and renal Doppler for early acute kidney injury diagnosis in hepatitis C virus cirrhosis
Fatma M Attia Elsayed, Mona Mahmoud Eladl, Magy Magdy Mohamed, Amira A A Othman
Amira A A Othman, Department of Internal Medicine, Faculty of Medicine, Suez University, Suez 43511, Egypt
Magy Magdy Mohamed, Department of Clinical Pathology, Faculty of Medicine, Zagazig University, Zagazig 44511, Egypt
Mona Mahmoud Eladl, Department of Radiology, Faculty of Medicine, Zagazig University, Zagazig 44511, Egypt
Fatma M Attia Elsayed, Department of Internal Medicine, Faculty of Medicine, Zagazig University, Zagazig 44511, Egypt
Author contributions: Othman AAA, Mohamed MM, Eladl MM, and Elsayed FMA were responsible for concept and design of the study, data acquisition, statistical analysis, interpretation of the results, analysis of the data, drafting of the manuscript, critically revising the manuscript, approval of the final version to be published, and agreement to be accountable for all aspects of the work.
AI contribution statement: Grammarly Premium was used solely for language editing, including correction of grammar, spelling, and clarity of expression. No generative AI tools such as ChatGPT or others were used.
Institutional review board statement: Ethical approval was obtained from the Institutional Review Board of Suez University (No. 9-SU-Med-2023). The approved study protocol identified Zagazig University Hospitals as the recruitment and data collection site.
Clinical trial registration statement: The study protocol was prospectively registered at the Pan African Clinical Trials Registry (PACTR202505555006910; registration date: April 18, 2025).
Informed consent statement: All participants provided informed consent.
Conflict-of-interest statement: All authors declare no conflict of interest in publishing the manuscript.
CONSORT 2010 statement: The authors have read the CONSORT 2010 Statement, and the manuscript was prepared and revised according to the CONSORT 2010 Statement.
Data sharing statement: All summarized findings are included in this published article. The datasets generated and analyzed during the current study are available from the corresponding author upon reasonable request.
Corresponding author: Amira A A Othman, MD, PhD, Lecturer, Principal Investigator, Department of Internal Medicine, Faculty of Medicine, Suez University, Cairo-Suez Road, Suez 43511, Egypt. amira.othman@med.suezuni.edu.eg
Received: February 2, 2026
Revised: February 7, 2026
Accepted: March 24, 2026
Published online: September 25, 2026
Processing time: 194 Days and 20.3 Hours
Abstract
BACKGROUND

Acute kidney injury (AKI) complicates up to 65% of hospitalizations for decompensated cirrhosis and is associated with high short-term mortality. Traditional markers such as serum creatinine are unreliable in cirrhosis, while novel biomarkers like neutrophil gelatinase-associated lipocalin (NGAL), cystatin C, and Doppler renal resistive index (RRI) show promise but have not been systematically validated in hepatitis C virus-endemic, resource-limited settings such as Egypt.

AIM

To evaluate the diagnostic and prognostic utility of NGAL, cystatin C, and RRI for early AKI detection, subtyping [pre-renal, hepatorenal syndrome (HRS), acute tubular necrosis (ATN)], and mortality risk stratification in cirrhotic patients.

METHODS

In this prospective cohort study, 120 cirrhotic patients with ascites were enrolled and categorized into three groups: Non-AKI (n = 42), pre-renal AKI (n = 43), and intrinsic AKI (n = 35), the latter subdivided into HRS (n = 20) and ATN (n = 15). Serum NGAL and cystatin C were quantified using commercially available enzyme-linked immunosorbent assay kits; RRI was obtained via standardized Doppler ultrasonography. AKI was staged per International Club of Ascites-Kidney Disease Improving Global Outcomes guidelines. To reflect real-world presentation, the cohort included both prevalent (present at admission) and incident (developing postadmission) AKI cases. Diagnostic performance was assessed using receiver operating characteristic analysis, and Cox regression models evaluated 30-day mortality. An NGAL-RRI-based machine-learning model (XGBoost) was developed for AKI subtyping, and a decision-tree model was constructed. Point-of-care ultrasound was associated with the reclassification of 42% of diagnostically ambiguous AKI cases.

RESULTS

AKI was present in 65% (78/120) of patients. Of these, 52 (66.7%) had AKI at admission, and 26 (33.3%) developed AKI during hospitalization. NGAL distinguished AKI with area under the curve (AUC) of 0.91 (95%CI: 0.87-0.95) [cutoff > 150 ng/mL, sensitivity of 90% (85%-94%), specificity of 85% (78%-90%)]. RRI > 0.74 identified HRS with AUC of 0.89 (95%CI: 0.83-0.94) with sensitivity of 82%, specificity of 88%. Cystatin C showed moderate diagnostic value [AUC of 0.86 (95%CI: 0.81-0.91)]. Urinary granular casts were specific for ATN (100%), while renin and aldosterone levels were highest in HRS. NGAL > 150 ng/mL was independently associated with higher 30-day mortality (hazard ratio = 3.1, 95%CI: 1.7-5.5), while RRI > 0.74 was associated with poor renal recovery (hazard ratio = 2.2, P = 0.003). The internally validated NGAL-RRI XGBoost model achieved a cross-validated AUC of 0.92 for AKI subtyping. Excluding borderline fractional excretion of sodium cases improved HRS AUC from 0.91 to 0.93. Implementation of an NGAL-guided triage protocol corresponded to a 28% lower rate of intensive care unit transfers in a simulated decision framework (14/50 avoided).

CONCLUSION

NGAL and RRI outperform creatinine in early AKI detection, subtyping, and prognostication in cirrhotic patients, while cystatin C adds diagnostic value, particularly in ambiguous cases. An NGAL-RRI-based algorithm, enhanced by cystatin C when needed, represents a practical, resource-efficient tool for AKI triage in resource-limited settings.

Keywords: Neutrophil gelatinase-associated lipocalin; Renal Doppler; Acute kidney injury; Cirrhosis; Biomarkers; XGBoost; Resource-efficient

Core Tip: Acute kidney injury (AKI) in cirrhosis is frequently underdiagnosed in resource-limited settings due to the unreliability of serum creatinine. This prospective Egyptian study, conducted in the hepatitis C virus-endemic population, demonstrates that integrating serum neutrophil gelatinase-associated lipocalin, cystatin C, and renal resistive index enables earlier AKI detection, accurate subtyping (pre-renal, hepatorenal syndrome, acute tubular necrosis), and improved short-term prognostication. We provide the first region-specific evidence that a simple neutrophil gelatinase-associated lipocalin-renal resistive index-based algorithm, supported by point-of-care ultrasound, can guide clinical triage and reduce unnecessary intensive care unit utilization in real-world Egyptian practice. These findings offer a practical, scalable diagnostic framework for cirrhosis-associated AKI in low-income and middle-income countries.

Write to the Help Desk